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Abstract: Voltage-gated sodium channels (VGSC) are the primary mediators of electrical 
signal amplification and propagation in excitable cells. VGSC subtypes are diverse, with 
different biophysical and pharmacological properties, and varied tissue distribution. 
Altered VGSC expression and/or increased VGSC activity in sensory neurons is 
characteristic of inflammatory and neuropathic pain states. Therefore, VGSC modulators 
could be used in prospective analgesic compounds. VGSCs have specific binding sites for 
four conotoxin families: μ-, μO-, δ- and ί-conotoxins. Various studies have identified that 
the binding site of these peptide toxins is restricted to well-defined areas or domains. To 
date, only the μ- and μO-family exhibit analgesic properties in animal pain models. This 
review will focus on conotoxins from the μ- and μO-families that act on neuronal VGSCs. 
Examples of how these conotoxins target various pharmacologically important neuronal 
ion channels, as well as potential problems with the development of drugs from 
conotoxins, will be discussed. 
Keywords: voltage-gated sodium channel; Nav1.3; Nav1.7; Nav1.8; Nav1.9; μ-conotoxin; 
μO-conotoxin; nociception; analgesic; pain 
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1. Introduction 
Depolarization-activated sodium (Na+)-selective ion channels (also known as voltage-gated sodium 
channels, VGSCs) are large transmembrane proteins present in central and peripheral neurons, and 
skeletal, cardiac and smooth muscle. In response to a small depolarization of the membrane potential, 
VGSCs cause a large depolarization by facilitating Na+ entry into the cell. This signal amplification is 
responsible for initiating and propagating action potentials, and is the defining property of excitable 
cells [1].  
VGSCs consist of a 260 kD pore-forming α-subunit, of which there are nine identified mammalian 
subtypes (Nav1.1–Nav1.9). Each subtype has distinct tissue distribution and biophysical properties.  
α-Subunits have intracellular N- and C-termini and consist of four homologous domains (DI–IV). 
Each domain contains six transmembrane-spanning helices (S1–S6) and can be broken down into two 
segments. The first is the S1–S4 segment, known as the voltage sensor, in which the positively charged 
S4 transmembrane segment moves in response to voltage and couples this movement to opening and 
closing of the pore domain. The second is the S5-P loop-S6, where ion selectivity and  
permeation occur.  
The structure of bacterial sodium channels NavAb and NavRh in various states have recently been 
determined to atomic resolution by X-ray crystallography [2–4]. A number of novel structural features 
were identified, including a short selectivity filter and ion selectivity determined by interactions with 
glutamate side chains [2]. Intriguingly, the crystal structures show that the channel lumen is penetrated 
by fatty acyl chains, via lateral fenestrations from the membrane. The fatty acyl chains extend into the 
central cavity, perhaps allowing small, hydrophobic channel modulators reach their binding site [2]. 
Studies of various toxins and drugs that interact with VGSCs have revealed clustered interaction sites 
on the channel. To date, nine distinct neurotoxin/drug receptor binding sites have been characterized 
on VGSC α-subunits (receptor sites 1–9) [5,6]. 
Most VGSC subtypes are blocked by nanomolar concentrations of puffer fish poison, tetrodotoxin 
(TTX), so are classified as TTX-sensitive (TTX-S) VGSCs. Conversely, several VGSC subtypes, such 
as Nav1.5, Nav1.8 and Nav1.9, are insensitive to nanomolar concentrations of TTX, so are classified as 
TTX-resistant (TTX-R) VGSCs [7]. TTX resistance has been linked to a single mutation in a residue in 
the channel pore. In TTX-S VGSCs, this residue is a tyrosine or phenylalanine (Y401 in Nav1.4), 
which is one residue external to the selectivity filter ring in DI (DEKA locus). However, in TTX-R 
channels, this residue is a cysteine or serine, which provides an unfavorable interaction with TTX, 
reducing the binding affinity for TTX in the pore [8,9]. 
VGSC α-subunits alone can form functional channels, but they may be associated with one or two 
auxiliary β-subunits, of which there are four known subtypes: β1 (36 kD), β2 (33 kD), β3 (25 kD) and 
β4 (38 kD). β-subunits comprise a single transmembrane segment, short intracellular C-terminus and 
large extracellular N-terminal domain harbouring two β-sheets in an immunoglobulin-like fold. 
Adding β-subunits to channel-forming α-subunits changes channel kinetics and voltage-dependent 
gating to that normally seen in native cells. Modulation of VGSC α-subunits by β-subunits is thought 
to mainly occur via interaction between the extracellular domains of both subunits [10]. However, two 
studies suggest the intracellular domains of VGSC α- and β-subunits also interact, and that this 
interaction may be important for modulating certain VGSC subtypes [11,12].  
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2. VGSC Subtypes Involved in Pain 
Chronic pain can be generally classified as inflammatory or neuropathic. Inflammatory pain is 
caused by tissue injury or inflammation, and usually disappears as soon as the healing process ends. It 
includes muscle pain, headache and pain associated with cancer. Inflammatory pain can often be 
relieved through using non-steroidal anti-inflammatory drugs and/or morphine derivatives. 
Neuropathic pain may be caused by nerve injury. It is usually accompanied by a burning sensation and 
only slightly relieved by anaesthetics, anticonvulsants and tricyclic antidepressants [13,14]. Unlike 
inflammatory pain, neuropathic pain is generally characterized by allodynia, when a normally  
non-painful stimulus is painful. Neuropathic pain is estimated to affect millions of people  
worldwide [15]. It reduces the affected person’s overall health and quality of life, while generating 
healthcare costs several times higher than those for control groups [16,17]. 
The molecular basis of inflammatory and neuropathic pain appears to involve changes in ion 
channel activity and/or expression levels, including that in VGSCs. For example, changes in VGSC 
expression in sensory neurons changes neuronal excitability [18–29]. VGSC subtypes Nav1.3, Nav1.7, 
Nav1.8 and Nav1.9 are believed to be specifically involved in transmitting pain signals. Irregular 
function of these VGSCs has been shown to produce harmful or even fatal channelopathies [30]. 
Therefore, therapeutics designed to target one of these four VGSC isoforms must be highly selective. 
Certain groups of sensory neurons are the main mediators of pain sensation. Sensory neurons 
transmit information from the periphery to the spinal cord. The spinal cord then transfers this 
information to the brainstem and forebrain. Nerve damage may cause hyperexcitability by increasing 
the firing frequency and/or generation of spontaneous action potentials from dorsal root ganglion 
(DRG) neurons [31].  
2.1. Nav1.3 
Nav1.3 is a TTX-S VGSC subtype normally expressed in the central nervous system (CNS). More 
Nav1.3 is usually expressed in embryogenesis than adulthood [32], but expression levels increase in 
peripheral DRG neurons after nerve injury and inflammation [33]. This suggests Nav1.3 plays a role in 
pain sensation [34]. Nav1.3 is also up-regulated in mammalian DRGs after spinal cord [35] and motor 
fiber injury [36]. Patients with trigeminal neuralgia have increased Nav1.3 expression in gingival  
tissue [37].  
Nav1.3 has faster kinetics and recovers more quickly from inactivation than TTX-R VGSCs [38]. 
Therefore, it could play an important role in high-frequency firing, as seen in chronic pain  
states [22,39]. Reducing Nav1.3 expression in pain-sensing peripheral neurons has been shown to 
diminish hypersensitivity in DRGs and pain [33]. However, Nassar et al. showed that Nav1.3  
knock-out mice still exhibit normal neuropathic pain behaviour and ectopic discharges from damaged 
nerves [40]. This suggests there may be a possible compensation mechanism in knock-out mice.  
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2.2. Nav1.7  
Nav1.7 is a TTX-S VGSC subtype, predominantly restricted to the peripheral nervous system 
(PNS), sensory and sympathetic neurons, and Schwann and neuroendocrine cells [41–45]. It displays 
rapid activation and inactivation kinetics [46].  
Recently, Nav1.7 received attention as a possible therapeutic target for drugs to treat pain. 
Mutations in the SNC9A gene, which encodes Nav1.7, have been shown to produce or prevent pain. 
Gain-of-function mutations, which produce pain, lead to a syndrome called ‘primary erythromelalgia’, 
a paroxysmal extreme pain disorder [47,48]. This syndrome is characterized by severe burning pain 
and redness in the extremities. In contrast, loss-of-function mutations, which prevent pain, lead to a 
syndrome called ‘congenital insensitivity to pain’ or ‘congenital analgesia’ [49–51]. This divergent 
spectrum, from feeling no pain to feeling constant pain, makes Nav1.7 an interesting potential 
therapeutic target. Consequently, Nav1.7 blockers are prospective analgesic compounds. For example, 
a peripherally acting Nav1.7-specific blocker, N-[(R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-
tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-2-(2-fluorophenyl)-ethyl]-4-fluoro-2-trifluoromethyl-
benzamide (BZP), has been shown to be as effective as the analgesic drugs gabapentin and mexiletine 
in reversing hyperalgesia and allodynia in rat models of inflammatory and neuropathic pain, but did 
not impair motor function [52]. 
Nav1.7 has also been shown to be necessary for odour perception in rats, mice and humans [53]. 
Humans with loss-of-function mutations in the SCN9A gene couldn’t detect odours, and although 
Nav1.7-null mice neurons still produced odour-evoked action potentials, they couldn’t initiate synaptic 
signalling from their axon terminals at the first synapse in the olfactory system. As a result, these mice 
no longer displayed vital, odour-guided behaviours [54]. Nav1.7 has also been shown to be expressed 
in rat olfactory sensory axons and is present in vomeronasal axons, indicating a role for Nav1.7 in 
transmitting pheromonal cues [55]. In addition, neuroepithelial injury caused transient expression of 
Nav1.7 by dendritic cells of monocytic lineage, suggesting an emerging role for this channel in 
immune function [55].  
2.3. Nav1.8  
Although Nav1.8 is selectively expressed in sensory neurons and C-type nerve fibers involved in 
nociception, mediating a slow-inactivating, TTX-R Na+ current, its precise role in pain is unclear. 
Peripheral nerve injury has been shown to reduce Nav1.8 expression in damaged neurons, indicating 
that Nav1.8 does not contribute to neuropathic pain [56]. However, Nav1.8 has also been shown to 
redistribute to the axons of uninjured sciatic nerves after spinal nerve ligation, indicating it plays a 
crucial role in pain states [56]. Zimmermann et al. also showed that Nav1.8 is essential for nociception 
in the cold and for cold pain [57]. Changes in Nav1.8 gene expression are partially attributed to 
changes in growth factor levels and altered auxiliary β-subunit expression levels [58,59].  
Nav1.8 knock-out mice display increased pain behaviour in comparison with wild-type mice, 
providing further evidence for a major role for this channel in pain [18,60,61]. Furthermore, discovery 
of the μO-conotoxin MrVIB, a potent and preferential Nav1.8 inhibitor, has provided evidence that 
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blocking Nav1.8 can alleviate chronic pain in rats [61,62]. Nevertheless, the role of Nav1.8 in 
neuropathic pain remains a matter for debate [37,45,60,63–65].  
2.4. Nav1.9 
Nav1.9 is a TTX-R VGSC subtype whose expression is restricted to the PNS. Its amino acid 
sequence exhibits only around 50% homology to that of other VGSCs. Nav1.9 elicits extraordinarily 
slow persistent currents and its activation kinetics are too slow to contribute to the action potential’s 
upstroke. Accordingly, Nav1.9 probably depolarizes the resting membrane potential, lowering the 
threshold for initiating action potentials [66–68].  
Studies using Nav1.9-null mice suggest this subtype plays a predominant role in inflammatory, but 
not neuropathic, pain [69,70]. However, the role of Nav1.9 in inflammatory pain is not completely 
clear, because Nav1.9 knockdown mediated by anti-sense oligodeoxynucleotides doesn’t reduce 
thermal hypersensitivity associated with complete Freund’s adjuvant-induced inflammatory pain [71]. 
It has been suggested that Nav1.9-mediated currents are down-regulated after nerve injury, but other 
studies contradict this idea [22,64].  
3. Conotoxins 
Conotoxins are small peptides in the venom of predatory, tropical marine cone snails from the 
genus Conus. Cone snails can be divided into three groups based on their primary prey: piscivorious 
(fish-hunting), vermivorous (worm-hunting) or molluscivorious (mollusc-hunting).  
Cone snails first synthesize propeptides in the secretory cells of their tubular venom duct. The 
precursor protein is then cleaved by proteases, generating active conotoxins that form key constituents 
of the venom. The cone snail injects its venom into prey using a harpoon-like, specialized radular  
tooth [72]. Venom is primarily used to immobilize prey, giving the cone snail sufficient time to engulf 
it, but can also be used for defense. Although injecting venom typically rapidly paralyzes prey, there 
are documented cases of venom from some fish-hunting species (e.g., Conus geographus) causing 
human fatalities [73,74].  
All cone snail venoms are complex, with each cone snail species producing a cocktail of more than 
1000 distinct peptides in the venom [75]. These peptides have a diverse range of pharmacological 
targets, including membrane ion channels like VGSCs. To date, four conotoxin families that target 
VGSCs have been identified: μ-, μO-, δ- and ί-conotoxins. Each of these families interact with VGSCs 
by binding to specific sites on the channel protein.  
μ-Conotoxins (Table 1) inhibit the current through open VGSCs by sterically and electrostatically 
blocking the ion-conducting pathway by binding to the outer vestibule of the channel [76]. Similar to 
μ-conotoxins, μO-conotoxins (Table 2) also inhibit VGSC currents. However, they do this by binding 
to a site external to the pore, which modifies channel gating and closes the channel [77].  
Recently two new conotoxins of the Τ-superfamily (two disulfide bonds), Cal12a and Cal12b, 
isolated from Conus californicus and one of the O2-superfamily (four disulfide bonds), LtVD, from 
Conus litteratus have been identified [78,79]. These peptides have been shown to inhibit VGSCs in 
either rat DRG neurons (LtVD [79]) or squid stellate ganglia neurons (Cal12a, Cal12b [78]). These 
disulfide-bonded peptides may represent new conotoxin families that target neuronal VGSCs.  
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Unlike μ- and μO-conotoxins, δ-conotoxins activate VGSCs. They do this by potentially interacting 
with hydrophobic surface residues of the S3/S4 linker of DIV, site 6. Domain IV is known to be 
critical for channel inactivation. This interaction extends channel openings, which prolongs action 
potentials and triggers persistent neuronal firing, ultimately delaying or inhibiting fast  
inactivation [73,80]. δ-Conotoxins consist of approximately 30 amino acids, contain three disulfide 
bonds that form an inhibitory cysteine knot, and are structurally similar to μO- and ω-conotoxins 
[81,82]. δ-Conotoxins from mollusc-hunting cone snails target only mollusc sodium channels and do 
not affect mammalian VGSCs. Very little is known about their subtype specificity [83–87].  
ί-Conotoxins also activate VGSCs, but unlike δ-conotoxins, do this without significantly affecting 
inactivation. They may do this by enhancing the amplitude of the TTX-S Na+ current in DRG neurons, 
or shifting the voltage dependence of activation to more hyperpolarized potentials. Both mechanisms 
do not affect the time course of inactivation [88,89].  
To date, the δ- and ί-conotoxins have not exhibited any analgesic activity and only limited data on 
their mode of action or subtype specificity is available. Therefore, in this review we will focus on μ- 
and μO-conotoxins. 
3.1. μ-Conotoxins 
μ-Conotoxins are highly basic, small, rigid peptides ranging from 16 to 26 amino acids long, and 
contain three disulfide bonds (Table 1). μ-Conotoxins bind to the pore region of VGSCs. Their 
selectivity for VGSC subtypes has been based predominantly on differences in the turret region  
(S5-P loop linker), because differences close to the pore are minimal [90].  
The first μ-conotoxin isolated and characterized was GIIIA from C. geographus. GIIIA was shown 
to be a potent and selective blocker of muscle VGSCs [91]. It inhibits the skeletal muscle VGSC, 
Nav1.4, with an IC50 in the low nanomolar range [92,93]. GIIIA’s ability to selectively target a single 
VGSC subtype suggests there may be other μ-conotoxins that could selectively target different VGSC 
subtypes, particularly those involved in pain signalling. Since the discovery of GIIIA, numerous  
μ-conotoxins with new sequences have been identified through molecular cloning techniques. Many of 
their structures have been solved using NMR spectroscopy (Figure 1) [94–98].  
The first μ-conotoxin shown to inhibit a neuronal VGSC was PIIIA. Despite having modest affinity 
for the neuronal channel Nav1.2 (~500 nM), PIIIA primarily blocks VGSCs in mammalian skeletal 
muscle [99].  
Another μ-conotoxin, KIIIA, was recently shown to preferentially bind to the neuronal channel 
Nav1.2 over the skeletal muscle channel Nav1.4. KIIIA also has a nanomolar affinity for Nav1.7, a 
VGSC involved in propagating pain signals [100]. Being only 16 amino acids long, KIIIA is 
considerably shorter than previously examined μ-conotoxins. The short length is due to fewer residues 
within the N-terminal half of the peptide, suggesting C-terminal residues are more critical for toxin 
binding than N-terminal residues.  
KIIIA and another small μ-conotoxin, SIIIA, have been shown to have analgesic properties in 
mouse inflammatory pain assays [101–103]. These μ-conotoxins have a framework that could be used 
to develop new analgesic drugs. Their small size, high affinity and unique VGSC channel selectivity 
make them strong prospective therapeutic agents.  
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Table 1. Neuronal voltage-gated sodium channels (VGSC) subtype selectivity and potency 
of μ-conotoxins. 
μ-Conotoxins Conus species 
Number of 
residues 
VGSC subtypes (IC50) References 
KIIIA C. kinoshitai 16 Nav1.3 (8 µM), 
Nav1.7 (100–290 nM) 
[100,101] 
SIIIA*/B C. striatus 20/20 Nav1.3 (11 µM (SIIIA)), 
Nav1.7 (65 µM (SIIIA)), 
Nav1.8 (insensitive to 10 µM) 
[103–105] 
PIIIA C. purpurascens 22 Nav1.3 (3.2 µM), 
Nav1.7 (3.1–6.2 µM) 
[96,106,107] 
GIIIA/B/C C. geographus 22/22/22 N.D.  
CnIIIA/B/C C. consors 22/25/22 Nav1.3 (11 µM (CnIIIA)), 
Nav1.7 (489 nM (CnIIIC)) 
Nav1.8 (insensitive to 1 µM 
(CnIIIC)) 
[98,107,108] 
CIIIA C. catus 22 N.D.  
SmIIIA C. stercusmuscarum 22 Nav1.3 (40 nM), 
Nav1.7 (1.3 µM) 
[97] 
MIIIA C. magus 22 Nav1.3 (7.7 nM), 
Nav1.7 (97 µM) 
[107] 
SxIIIA/B C. striolatus 22/23 N.D.  
BuIIIA/B/C C. bullatus 23/24/26 Nav1.3 (350 nM (BuIIIA); 200 nM 
(BuIIIB)) 
[107] 
TIIIA C. tulipa 22 Nav1.3 (50 nM), 
Nav1.7 (insensitive to 3 µM) 
Nav1.8 (insensitive to 3 µM) 
[107] 
N.D., not determined. *commercial name PEG-SIIIA; entered pre-clinical trial for inflammatory pain (i.v.) [109]. 
μ-Conotoxins bind to the outer vestibule to inhibit current through the channel. To understand 
which of the four channel domains are critical to binding, chimeras between rat Nav1.4 (rNav1.4) and 
human Nav1.5 (hNav1.5) or human Nav1.8 (hNav1.8) have been constructed and examined [104,108]. 
These studies showed that SIIIA and CnIIIC are potent blockers of the VGSC subtypes Nav1.2 and 
Nav1.4, but inactive at Nav1.8 and Nav1.5. The studies further revealed that determinants for the 
toxin’s inability to block Nav1.8 were located across all domains of the channel, whereas those for 
Nav1.5 were restricted to DI and DII.  
There are few differences among the VGSC isoforms in the pore region near the inner and outer 
ring charge groups (important for ion selectivity and permeation) of the outer vestibule in each of their 
four channel domains. However, a single amino acid residue change in this region has been shown to 
be critical for classical pore blockers saxitoxin and TTX [7]. This residue is located in DI, one residue 
outside the selectivity filter aspartate. It is either a tyrosine or phenylalanine in TTX-S channels, and a 
serine or cysteine in TTX-R sodium channels.  
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This variation among sodium channel isoforms also affects μ-conotoxin binding properties, such as 
affinity, but this change is modest [100,110]. Nevertheless, it modulates the actions of various  
μ-conotoxins analogues that incompletely block single channel currents [106]. Potential derivatives 
that do not completely block single channel currents could fine tune hyperexcitability. Derivatives of 
GIIIA and PIIIA as well as KIIIA and its derivatives, which have been examined at the single channel 
level, cannot completely block single channel currents [93,101,110] and could be used in this way. A 
drug that modulates single-channel currents would be an effective treatment to reduce 
hyperexcitability without eliminating Na+ channel currents completely. 
An additional variation in the sequence in this VGSC region is attractive to examine because it may 
identify potential human Nav1.7 (hNav1.7) blockers. Human Nav1.7 is the only VGSC subtype, from 
any species, where the DIII outer ring charge (typically an aspartate) has been replaced by a neutral 
isoleucine. μ-Conotoxin binding affinity is critically influenced by residues in the outer ring, especially 
those of DI and DII [111–113]. Recent studies using KIIIA showed that charges interacting with this 
outer ring charge, when neutralized, affected the derivative’s affinity for hNav1.7 much less than its 
affinity for Nav1.2 and Nav1.4 [100]. The missing outer ring charge of hNav1.7 is believed to be the 
best site to engineer toxin specificity towards hNav1.7. For example, in KIIIA, the derivative H12Q, 
which, based on molecular dynamics docking simulations, should interact with the DIII outer ring 
charge, increased toxin selectivity for hNav1.7 over Nav1.2 and Nav1.4. The R14A derivative increased 
the toxin’s selectivity for hNav1.7 to 10-fold more than that for Nav1.2 and Nav1.4 [100]. This is the 
first example of an engineered μ-conotoxin that is selective for hNav1.7. This μ-conotoxin interaction 
site is a potential target for designing hNav1.7-specific blockers, which could increase selectivity 
towards Nav1.7 and decrease the risk of possible side effects. 
3.2. μ-Conotoxin Engineering 
Recent studies using new peptide synthesis techniques are shedding light on how to create stable 
and selective sodium channel modulators, and identifying new drug leads. Peptides as drug leads have 
a few drawbacks, such as unstable disulfide bonds, protease degradation and inefficient transport of the 
peptide to its intended site of action. To address these concerns, researchers have been trying to 
improve the native µ-conotoxin by creating more stable peptide bridges, using truncated peptides 
and/or peptide mimetics. They have also used μ-conotoxins as scaffolds to enhance the peptide’s 
potential as a drug.  
μ-Conotoxins have three disulfide bonds, which can be oxidized and reduced, and refolded to 
inactive conformations. This was examined in detail for PIIIA, where three PIIIA isomers were created 
with different disulfide connections [114]. Despite differences in connectivity, the three derivatives all 
had sub-micromolar affinity for Nav1.4. This suggests that, despite the toxin preferring to fold to a 
single conformation, other conformations could also be active. It will be of interest to examine these 
different PIIIA isomers to determine if they exhibit different selectivity to that of the native toxin.  
To make the peptide structure stable, different non-disulfide bonds can also be introduced. For 
example, SIIIA with diselenide bridges instead of disulfide bridges was recently synthesized [115]. 
Diselenide bonds are considerably more stable than disulfide bonds, making the μ-conotoxin itself 
more stable [116]. 
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With many new μ-conotoxin sequences being discovered, there seems to be greater divergence in 
the N-terminus half of the toxin sequence. For example, KIIIA seems to be missing many more 
residues in the N-terminus than other µ-conotoxins. It may be interesting to examine the effects of 
smaller μ-conopeptides by removing N-terminal residues. Several groups recently examined short 
peptides based on KIIIA and SIIIA, with varying success. Norton and colleagues used lactam bridges 
to stabilize the α-helical segment of μ-conotoxins [117,118]. This segment has most of the critical 
residues for toxin binding and might be used as a template on which to base drug design. KIIIA and 
BuIIIC were used to design ‘mini peptides’ ranging from 12 to 16 amino acids, to try to understand the 
pharmacophore of μ-conotoxins [119,120].  
In contrast with these two studies, adding residues to the N-terminus of SIIIA, SIIIB and TIIIA has 
been shown to change their selectivity preference from rat muscle channels to rat neuronal VGSCs 
[121]. This suggests that N-terminal residues also contribute to the toxins’ affinity and selectivity. 
As peptides are degraded or truncated by proteases, non-peptide backbones have also been 
examined to try to increase drug bioavailability. KIIIA and SIIIA structure has undergone non-peptide 
modification to help design new drug leads. For example, Bulaj and colleagues examined the effects of 
removing a single disulfide bond to see if it is feasible to use non-peptide backbone spacers and 
disulfide bond deletion to increase bioavailability without decreasing affinity or change selectivity. 
They also used amino-3-oxapentanoic or 6-aminohexanoic acids to replace non-essential amino acids 
in the toxin to further minimize the protein component of the toxin [103,122]. Resulting analogues still 
inhibited VGSCs and produced analgesic effects.  
μ-Conotoxins as potential analgesics are still in the preclinical stage. We are learning how these 
unique toxins can block specific VGSC subtypes, and how we can modify them without changing their 
selectivity and high affinity for VGSCs. As we further examine these toxins and isolate new toxins that 
can block specific VGSC subtypes, we will be able to design new selective and clinically relevant 
drugs to block VGSC subtypes involved in pain signalling. 
3.3. μO-Conotoxins 
μO-Conotoxins are hydrophobic peptides belonging to the O-superfamily of conotoxins. This group 
of toxins was first isolated from Conus marmoreus [82]. To date, five μO-conotoxins have been 
discovered (Table 2). They range from 28 to 32 amino acids in length, with each toxin containing three 
intramolecular disulfide bonds. Two of these μO-conotoxins, MrVIA and MrVIB, have  
high sequence homology. Only two residues differ between them. MrVIA and MrVIB are of interest 
because they block TTX-R Na+ currents in mammalian DRG neurons (which are mainly mediated by 
Nav1.8) 10-fold more than TTX-S Na
+ currents [62,123,124]. However, despite the selectivity of 
MrVIA and MrVIB for the TTX-R subtype Nav1.8 over TTX-S subtypes, and the resulting analgesic 
activity in a variety of animal models of pain [62,123–125], little is known of the structure–activity 
relationships that define µO-conotoxin subtype specificity.  
MrVIA inhibits VGSCs and voltage-gated calcium channels (VGCC) in Aplysia californica and 
Lymnaea stagnalis molluscan neurons [82], and amphibian VGSCs [124]. It also inhibits TTX-S Na+ 
currents in rat hippocampal neurons and heterologously expressed rNav1.2 in Xenopus oocytes with 
IC50 values of 200 nM [126]. MrVIA blocks TTX-R VGSCs from rDRG neurons with an IC50 of 82.8 
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nM [125]. Consistent with μO-conotoxins acting as gating modifiers, MrVIA inhibition of Na+ current 
appears to be voltage-dependent, with a reduced affinity for the channel after depolarizing voltage 
steps [77,127].  
MrVIB more selectively inhibits TTX-R than TTX-S neuronal VGSCs, and is also selective 
between different TTX-R VGSC subtypes. It is 100-fold more selective for Nav1.8 than Nav1.9 in 
DRGs [62]. Its selectivity for hNav1.8 over other VGSC subtypes was confirmed using Xenopus 
oocytes expressing a range of different VGSC subtypes [62]. This is particularly interesting, since only 
a few Nav1.8-selective modulators have been described to date. Zorn et al. also showed that MrVIB is 
more selective for Nav1.4 than Nav1.2 expressed in HEK 293 cells [128].  
MrVIB has exhibited analgesic activity in animal pain models and decreased mechanical and 
thermal pain sensation [62,125]. Intrathecally applied MrVIB was 30 times more effective than 
lidocaine on allodynia and hyperalgesia and had only small motor system side effects [62]. The 3D 
structure was determined using NMR data (Figure 1) [125].  
Figure 1. Structures and sequences of analgesic µ- and µO-conotoxins. (A) Solution 
structures of analgesic µ-conotoxins, KIIIA and SIIIA. Disulfide links (green) with critical 
lysine (cyan, K7 (KIIIA) and K11 (SIIIA)) and arginine (blue, R14 (KIIIA) and R18 
(SIIIA)) residues. (B) Solution structure of analgesic µO-conotoxin MrVIB. Disulfide links 
are green. (C) Amino acid sequences of analgesic µ-conotoxins, KIIIA and SIIIA, and  
µO-conotoxins, MrVIA and MrVIB. * C-terminal amidation. 
 
There is considerable interest in finding out how µO-conotoxins bind to VGSCs, since they are 
modestly selective inhibitors of TTX-R VGSC currents in rat DRG neurons [125] and have potential as 
analgesic drugs [62,123,124]. Analysis of the MrVIA binding site in rNav1.4 channels and competition 
experiments with the scorpion toxin, β-toxin Ts1, identified that the C-terminal pore loop of DIII is 
necessary for MrVIA to bind to Nav1.4 [128]. In contrast, a later study using site-directed Nav1.4 
mutagenesis, revealed that DII’s voltage sensor is the main MrVIA binding site. The same study 
concluded that MrVIA interaction with DIII of Nav1.4 appeared to play a lesser role [77]. Neither of 
these two studies examined the binding site and mechanism of action of µO-conotoxins on Nav1.8.  
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Figure 2. Effect of µO-conotoxin MrVIB on Na+ current amplitude of Nav1.2, Nav1.8 and 
their chimeras. (A) Schematic diagram of parent VGSC α-subunits rNav1.2 (open), 
hNav1.8 (filled) and chimeras 8822 and 8288. Roman numerals denote individual domains 
of the α-subunit, (B) Current–voltage relationship of rNav1.2, hNav1.8 and chimeras 8288 
and 8822 in the absence (open symbols) and presence (closed symbols) of 1 μM MrVIB. 
Normalized peak currents (I/I0) were plotted as a function of membrane potential. Insets: 
normalized depolarization-activated Na+ currents in Xenopus oocytes expressing rNav1.2, 
hNav1.8 and the chimeras. Oocytes were held at −80 mV and depolarized to potentials 
ranging from −80 to +40 mV in 10 mV increments (adapted from Knapp et al. [129]).  
 
Nav1.8 is only 50% identical to Nav1.2, a major VGSC of the central nervous system, and its 
affinity for MrVIB is higher than that of Nav1.2 [62]. To address the functional and pharmacological 
significance of these differences, Knapp et al. used a domain swapping strategy between rNav1.2 and 
hNav1.8 [129]. Heterologous expression of Nav1.2/Nav1.8 chimeras in Xenopus oocytes and analysis of 
their inhibition by MrVIB revealed that the region between segment S6 of DI and the external loop of 
DII in Nav1.8 is the main determinant for the μO-conotoxin family’s high affinity for Nav1.8  
(Figure 2) [129]. Comparing this data with those of Leipold et al. supports the likelihood that MrVIB 
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inhibition of Nav1.8 is mediated via an interaction between the toxin and DII’s voltage sensor [77,129]. 
A similar approach was used to study the interaction between Nav1.9 voltage sensors and scorpion or 
tarantula toxins. The voltage-sensor paddle motifs of Nav1.9 were transferred into the voltage-gated 
potassium channel Kv2.1 [130]. This enabled examination of their interactions with tarantula and 
scorpion toxins [131]. The possibility that MrVIB could also interact with other domains cannot be 
excluded. Results from recent studies into MfVIA inhibition of Nav1.2 and other voltage-sensor toxins 
such as tarantula toxins may support the idea of multiple binding sites [132,133]. 
MfVIA, a novel µO-conotoxin, was recently identified from Conus magnificus. Similar to MrVIA 
and MrVIB, it is a hydrophobic peptide containing 32 residues, but has highest sequence homology to 
MrVIB [133]. MfVIA’s amino acid sequence is only slightly different to those of MrVIA and MrVIB. 
Surprisingly, this results in MfVIA having different potencies and selectivity towards mammalian 
VGSC subtypes from those of MrVIA and MrVIB. MfVIA is three-fold more potent towards Nav1.4 
and five-fold less potent towards Nav1.2 than MrVIA or MrVIB. MfVIA inhibits TTX-R Na
+ currents 
expressed in DRG neurons five times more strongly than those heterologously expressed in rNav1.8. It 
also inhibits Nav1.4 and Nav1.8 at low nanomolar concentrations, whereas significantly higher toxin 
concentrations are needed to inhibit all other VGSC subtypes (Table 2) [133].  
Table 2. Neuronal VGSC subtype selectivity and potency of μO-conotoxins. 
μO-Conotoxins Conus species 
Number of 
residues 
VGSC subtypes 
(IC50) 
References 
MrVIA C. marmoreus 31 Nav1.7 (345 nM) [123,134] 
MrVIB* C. marmoreus 31 
Nav1.3 (1 µM), 
Nav1.7 (345 nM), 
Nav1.8 (1–326 nM) 
[62,124,134] 
MfVIA C. magnificus 32 
Nav1.3 (2175 nM), 
Nav1.7 (2317–5491 nM), 
Nav1.8 (529 nM) 
[133] 
LtVIIA C. litteratus 29 N.D. [135,136] 
LtVIC C. litteratus 28 N.D. 
[135,136] 
 
N.D., not determined. *commercial name CGX-1002 (Cognetix Inc.); entered pre-clinical trial for 
neuropathic pain (i.t./i.v.) [109]. 
The established model of μO-conotoxin mediated block of VGSC channels involves a single toxin 
molecule binding and inhibiting the channel. This is consistent with MfVIA inhibition of all VGSC 
subtypes except Nav1.2. The concentration–dependence for Nav1.2 inhibition was steeper than the 
expected Hill slope of −1 [133]. This may indicate that MfVIA interacts with more than one binding 
site. Another possibility might be that μO-conotoxins have slow on-rates that make it difficult to reach 
equilibrium at low peptide concentrations [133].  
DNA sequencing of C. litteratus has revealed the existence of two novel μO-conotoxins, LtVIC and 
LtVIIA. These recombinant toxins inhibit Na+ currents in DRG neurons in a similar way to known  
μO-conotoxins. However, their subtype selectivity and structure–activity relationships are yet to be 
investigated [135–137].  
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MrVIA, MrVIB and MfVIA remain the only μO-conotoxins for which mammalian VGSC subtype 
selectivity data is available, albeit not across all VGSC subtypes. The unique selectivity profile of  
μO-conotoxins MfVIA, MrVIA and MrVIB [62,82,126,133] makes these peptides attractive leads for 
analgesic drugs [62,129]. Synthesis of μO-conotoxins does, however, pose significant challenges. This 
is mainly due to their highly hydrophobic nature and the difficulty of correctly forming their three 
disulfide bonds to the native isomer. While replacing cysteines with selenocysteines has helped with 
MrVIB folding [138], synthesis of the native molecule relies on a semi-selective approach [124,134], 
which produces a low overall yield. Nevertheless, a novel regioselective protocol has been developed 
for synthesizing the novel μO-conotoxin MfVIA that only uses a single HPLC purification step and 
increases peptide yields [133]. 
Another potential problem with μO-conotoxins is that their affinity for Nav1.4 and Nav1.8 is almost 
identical. This may limit their therapeutic effectiveness, unless derivatives of the toxins can make them 
more selective for Nav1.8 than Nav1.4. Stürzebecher et al. introduced a membrane-tethered isoform of 
MrVIA (t-MrVIA) into nociceptive neurones in mice, where it was successfully expressed on the cell 
surface [123]. TTX-R VGSC current densities, which were mainly Nav1.8-mediated, were reduced by 
44 ± 7% in t-MrVIA transgenic mice, without up-regulation of TTX-S VGSC, VGCC or transient 
receptor potential channel expression in nociceptive neurones [123]. t-MrVIA transgenic mice had less 
inflammatory mechanical hypersensitivity and firing of cutaneous C-fibres sensitive to noxious cold 
temperatures, and were more insensitive to cold pain than wild-type mice [123]. Besides proving that 
MrVIA is analgesic, membrane-tethered MrVIAs could be used to study and manipulate VGSCs in 
specific cell types in the mammalian nervous system [123], further increasing the toxin’s selectivity. 
4. β-Subunits Modulate the Effects of Conotoxins 
Auxiliary β1-, β2-, β3- and β4-subunits, when individually co-expressed with Nav1.8 in Xenopus 
oocytes, increased the kon of μO-MrVIB inhibition of Na
+ current by 3-, 32-, 2- and 7-fold,  
respectively [127]. β-subunits also modestly decreased the koff rate [127]. Different β-subunit 
expression rates, in combination with depolarizing prepulses, markedly accelerated MrVIB washout. 
Co-expression of β-subunits, in particular β2, with Nav1.8 α-subunits strongly influenced  
μO-conotoxin affinity for this subtype. However, expression of the α-subunit with auxiliary β-subunits 
did not appear to influence μ-conotoxin selectivity or affinity for Nav1.8 [107]. Whether or not this is 
also true for other members of this toxin family is yet to be determined [137]. 
5. Multiple Sites of µ- and µO-Conotoxin Action  
Many animal toxins that target multiple pharmacologically distinct ion channels or receptors have 
been identified in recent years. For example, MrVIA and MrVIB have been reported to inhibit mollusc 
and mammalian VGSCs, as well as mollusc VGCCs [82,107]. However, Daly et al. showed that 
mammalian VGCCs in DRG neurons were unaffected by these toxins. Therefore, it can be assumed 
that the analgesic effects evoked by MrVIA and MrVIB are unrelated to VGCCs [125].  
It was also recently shown that μ-conotoxin CnIIIC has multiple targets, including VGSCs and 
ligand-gated channels [98]. CnIIIC from Conus consors inhibited Nav1.4, with an IC50 of 1.3 nM, and 
α3β2 nicotinic acetylcholine receptor (nAChR) channels, with an IC50 of 450 nM. nAChR subtypes α7 
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and α4β2 were inhibited to a lesser extent, in the micromolar range [98]. The diversity of 
pharmacological interactions of conotoxins with different membrane receptors, transporters and ion 
channels should not be overlooked when developing new analgesics and other bioactive drugs. 
6. Conotoxins—Analgesics of the Future? 
Since their discovery, conotoxins have been of interest because of their high affinity and selectivity 
for VGSCs and other membrane receptors and ion channels. Neuropathic and inflammatory pain is 
associated with changes in VGSC activity and expression [25,139]. Because of this, several 
conopeptides are being investigated as anti-nociceptive drugs [73]. To date, however, no therapeutic 
drug that selectively targets a specific VGSC subtype is available. Despite the fact that several 
conotoxins have been and are currently being tested in clinical trials, only the ω-conotoxin MVIIA 
from Conus magus has been approved as an analgesic drug (Ziconitide, Prialt®) to treat intractable  
pain [140–142]. 
μO-Conotoxins MrVIA, MrVIB and MfVIA block Nav1.8, which has a major role in pain, but does 
not appear to be important for other physiological functions [18]. As such, these peptides have 
potential as new analgesics and are the focus of several studies. In particular, MrVIB reduces pain 
without causing motor deficits in animal models [62]. Of the μ-conotoxins, SIIIA and KIIIA have both 
shown analgesic activity in mouse models [101,105]. However, both peptides also target skeletal 
muscle sodium channels, which reduces their analgesic potential in their native form. Nonetheless, 
specifically designed derivatives of these peptides have the potential to increase selectivity towards 
VGSC pain targets [100]. 
Side effects from the native toxin must be expected and should be carefully assayed in detail. For 
example, μO-conotoxins also affect the muscle VGSC subtype Nav1.4, which may limit their 
therapeutic effectiveness [62,128]. Side effects are also a particular consideration for μ-conotoxins, 
because they target muscle and neuronal VGSC subtypes [99]. However, a major hurdle in developing 
conotoxins as analgesic drugs is creating a drug that targets a single VGSC subtype. So far, no toxin 
selective for only one VGSC subtype has been discovered. Furthermore, pharmacological interactions 
of conotoxins with membrane receptors and ion channels other than their target (e.g., VGSCs) can be 
underestimated. The same is true for other animal peptide toxins, for example spider toxins [143–145].  
Other problems associated with conotoxins include their challenging chemical synthesis and 
folding, which make it difficult to produce conopeptides in large quantities. Orally active drugs are 
also difficult to produce, although they are most desirable, because they would be better accepted by 
patients and doctors [146]. For example, MVIIA (Ziconitide, Prialt®) requires intrathecal 
administration which limits its range of applications. Despite these complications, conotoxins that 
inhibit VGSCs and have some subtype selectivity are valuable tools for studying ion channels and their 
physiological role. This will contribute to the development of novel drugs to improve pain 
management and treat neurological disorders. 
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